<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060189</url>
  </required_header>
  <id_info>
    <org_study_id>UTI Trial China</org_study_id>
    <nct_id>NCT01060189</nct_id>
  </id_info>
  <brief_title>Hemostatic and Anti-Inflammatory Effects of Ulinastatin and Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery</brief_title>
  <official_title>Hemostatic and Anti-Inflammatory Effects of Ulinastatin and Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antifibrinolytic drugs are used to decrease perioperative bleeding and allogeneic
      transfusions. The extensively studied antifibrinolytic drug aprotinin is efficacious but
      expensive, and has been proved to link to higher risks of serious side effects including
      renal problems, myocardial events, and strokes in patients undergoing CABG. After the
      secession of aprotinin in 2007, a marked increase of blood loss and transfusions in cardiac
      surgery took place. An effective and secure hemostatic agent is badly needed. Ulinastatin,
      urinary trypsin inhibitor(UTI), is a secreted Kunitz-type protease inhibitor with a wide
      inhibition spectrum, including plasmin. Limited studies offered clues to its antifibrinolytic
      effect. Tranexamic acid has been applied for years with convinced efficacy and safety. The
      objective of the study is to evaluate the hemostatic and anti-inflammatory effect of
      ulinastatin and tranexamic acid in cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative blood loss(chest drainage)</measure>
    <time_frame>on the 30th day postoperatively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Perioperative allogeneic transfusions</measure>
    <time_frame>on the 30th day postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of reexploration for bleeding</measure>
    <time_frame>on the 30th day postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU and hospital postoperatively</measure>
    <time_frame>on the 30th day postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulatory and fibrinolytic status</measure>
    <time_frame>6hrs, 12hrs and 24hrs postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory cytokines</measure>
    <time_frame>6hrs, 12hrs and 24hrs postoperatively</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Hemostasis</condition>
  <arm_group>
    <arm_group_label>Ulinastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,000,000 units after anesthetic induction 1,000,000 units after heparinization 1,000,000 units after neutralization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg after heparinization 15mg after neutralization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ulinastatin 1,000,000 units after anesthetic induction 1,000,000 units after heparinization 1,000,000 units after neutralization
Tranexamic Acid 15mg after heparinization 15mg after neutralization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline solution 50ml after anesthetic induction 50ml after heparinization 50ml after neutralization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UTI &amp; TA</intervention_name>
    <description>Ulinastatin, tranexamic acid and the combination of the two</description>
    <arm_group_label>Ulinastatin</arm_group_label>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Atrial or ventricular septum defect patients requiring cardiac surgery with CPB

          -  Rheumatic or recessive valvular patients requiring valvular repair or replacement with
             CPB

          -  Coronary artery disease patients requiring coronary revascularization with CPB

        Exclusion Criteria:

          -  Non-primary cardiac surgery

          -  Definite liver and renal dysfunction

          -  Disorder in coagulation function

          -  Allergy

          -  Pregnancy and lactation

          -  Disabled in spirit or law

          -  Fatal conditions such as tumour
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lihuan Li, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jia Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lihuan Li, MD</last_name>
    <phone>86-10-88398184</phone>
    <email>llhfw@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia Shi, MD</last_name>
    <phone>86-10-88398082</phone>
    <email>shiandypumc@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihuan Li, MD</last_name>
      <phone>86-10-88398184</phone>
      <email>llhfw@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Jia Shi, MD</last_name>
      <phone>86-10-88398082</phone>
      <email>shiandypumc@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lihuan Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jia Shi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>SHI Jia</investigator_full_name>
    <investigator_title>Attending doctor of the department of anesthesiology and critical care, Fuwai Hospital, NCCD, PUMC &amp; CAMS</investigator_title>
  </responsible_party>
  <keyword>ulinastatin</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>cardiac surgery procedures</keyword>
  <keyword>hemostasis</keyword>
  <keyword>anti-inflammation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Hemostatics</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Urinastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

